Glioblastoma stem cells: new insights in therapeutic strategies

Goffart, Nicolas; Dedobbeleer, Matthias; Rogister, Bernard

doi:10.2217/fnl.14.56

Request a copy

Other (Scientific journals)

Glioblastoma stem cells: new insights in therapeutic strategies

Goffart, Nicolas; Dedobbeleer, Matthias; Rogister, Bernard

2014 • In Future Neurology, 9 (6), p. 639-653

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/181975

DOI
10.2217/fnl.14.56

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Glioblastoma stem cells new insights in therapeutic strategies.pdf

Publisher postprint (1.13 MB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

chemotherapy; Glioblastoma; Glioblastoma stem cells; Immunotherapy; Radiotherapy; Surgery

Abstract :

[en] Despite notable achievements in glioblastoma diagnosis and treatment, the prognosis of glioblastoma patients remains poor and reflects the failure of current therapeutic modalities. In this context, innovative therapeutic strategies have recently been developed to specifically target glioblastoma stem cells, a subpopulation of tumor cells involved in experimental tumorigenesis and known to be critical for tumor recurrence and therapeutic resistance. The current review summarizes the different trails which make glioblastoma stem cells resistant to treatments, mainly focusing on radio-, chemo- and immunotherapy. This broad overview might actually help to set up new bases for glioblastoma therapy in order to better fight tumor relapses and to improve the patients’ prognosis.

Disciplines :

Oncology

Author, co-author :

Goffart, Nicolas ; Université de Liège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, et biochimie humaine

Dedobbeleer, Matthias ; Université de Liège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, et biochimie humaine

Rogister, Bernard ; Université de Liège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, et biochimie humaine

Language :

English

Title :

Glioblastoma stem cells: new insights in therapeutic strategies

Publication date :

November 2014

Journal title :

Future Neurology

ISSN :

1479-6708

eISSN :

1748-6971

Publisher :

Future Medicine Ltd, London, United Kingdom

Volume :

Issue :

Pages :

639-653

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 27 May 2015

Statistics

Number of views

105 (15 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genet. 205(12), 613-621 (2012).
Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21(21), 2683-2710 (2007).
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
Frosina G. DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol. Cancer Res. 7(7), 989-999 (2009).
Kaur B, Cork SM, Sandberg EM et al. Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res. 69(3), 1212-1220 (2009).
Claes A, Idema AJ, Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol. 114(5), 443-458 (2007).
Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1), 98-110 (2010).
Sottoriva A, Spiteri I, Piccirillo SG et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl Acad. Sci. USA 110(10), 4009-4014 (2013).
Hingtgen S, Figueiredo JL, Farrar C et al. Real-time multi-modality imaging of glioblastoma tumor resection and recurrence. J. Neurooncol. 111(2), 153-161 (2013).
Melguizo C, Prados J, Gonzalez B et al. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J. Transl. Med. 10, 250 (2012).
Hale JS, Sinyuk M, Rich JN, Lathia JD. Decoding the cancer stem cell hypothesis in glioblastoma. CNS Oncol. 2(4), 319-330 (2013).
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 414(6859), 105-111 (2001).
Galli R, Binda E, Orfanelli U et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64(19), 7011-7021 (2004).
Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63(18), 5821-5828 (2003).
Salmaggi A, Boiardi A, Gelati M et al. Glioblastoma-derived tumorospheRes. identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 54(8), 850-860 (2006).
Eramo A, Ricci-Vitiani L, Zeuner A et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 13(7), 1238-1241 (2006).
Stiles CD, Rowitch DH. Glioma stem cells: a midterm exam. Neuron 58(6), 832-846 (2008).
Goffart N, Kroonen J, Rogister B. Glioblastoma-initiating cells: relationship with neural stem cells and the micro-environment. Cancers (Basel) 5(3), 1049-1071 (2013).
Kubben PL, Ter Meulen KJ, Schijns OE, Ter Laak-Poort MP, Van Overbeeke JJ, Van Santbrink H. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol. 12(11), 1062-1070 (2011).
Senft C, Bink A, Heckelmann M, Gasser T, Seifert V. Glioma extent of resection and ultra-low-field iMRI: interim analysis of a prospective randomized trial. Acta Neurochir. Suppl. 109, 49-53 (2011).
Moiyadi A, Syed P, Srivastava S. Fluorescence-guided surgery of malignant gliomas based on 5-aminolevulinic acid: paradigm shifts but not a panacea. Nat. Rev. Cancer 14(2), 146 (2014).
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre Phase III trial. Lancet Oncol. 7(5), 392-401 (2006).
Beier D, Schulz JB, Beier CP. Chemoresistance of glioblastoma cancer stem cellsmuch more complex than expected. Mol. Cancer 10, 128 (2011).
Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. Cochrane Database Syst. Rev. 4, CD007415 (2013).
Reifenberger G, Hentschel B, Felsberg J et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int. J. Cancer 131(6), 1342-1350 (2012).
Thon N, Kreth S, Kreth FW. Personalized treatment strategies in glioblastoma: promoter methylation status. Onco Targets Ther. 6, 1363-1372 (2013).
Beier D, Rohrl S, Pillai DR et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 68(14), 5706-5715 (2008).
Okada M, Sato A, Shibuya K et al. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. Int. J. Oncol. 44(2), 591-599 (2014).
He J, Shan Z, Li L et al. Expression of glioma stem cell marker CD133 and O6-methyl guanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas. Oncol. Rep. 26(5), 1305-1313 (2011).
Hsieh A, Ellsworth R, Hsieh D. Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells. J. Cell Physiol. 226(4), 1118-1127 (2011).
Pistollato F, Abbadi S, Rampazzo E et al. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 28(5), 851-862 (2010).
Heddleston JM, Li Z, Mclendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8(20), 3274-3284 (2009).
Venere M, Hamerlik P, Wu Q et al. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death Differ. 21(2), 258-269 (2014).
Barazzuol L, Jena R, Burnet NG et al. Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. Radiat. Oncol. 8, 65 (2013).
Tentori L, Ricci-Vitiani L, Muzi A et al. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. BMC Cancer 14, 151 (2014).
ClinicalTrials.gov. ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme. https://clinicaltrials.gov
Capper D, Gaiser T, Hartmann C et al. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol. 117(4), 445-456 (2009).
Kahana S, Finniss S, Cazacu S et al. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCepsilon-dependent downregulation of AKT and XIAP expressions. Cell Signal. 23(8), 1348-1357 (2011).
Unterkircher T, Cristofanon S, Vellanki SH et al. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin. Cancer Res. 17(12), 4019-4030 (2011).
Bota DA, Alexandru D, Keir ST, Bigner D, Vredenburgh J, Friedman HS. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. J. Neurosurg. 119(6), 1415-1423 (2013).
El Hallani S, Boisselier B, Peglion F et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 133(Pt 4), 973-982 (2010).
Ricci-Vitiani L, Pallini R, Biffoni M et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468(7325), 824-828 (2010).
Wang R, Chadalavada K, Wilshire J et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468(7325), 829-833 (2010).
ClinicalTrials.gov. Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma. http://clinicaltrials.gov
ClinicalTrials.gov. Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma. https://clinicaltrials.gov
Rubin JB, Kung AL, Klein RS et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl Acad. Sci. USA 100(23), 13513-13518 (2003).
Ehtesham M, Winston JA, Kabos P, Thompson RC. CXCR4 expression mediates glioma cell invasiveness. Oncogene 25(19), 2801-2806 (2006).
Gatti M, Pattarozzi A, Bajetto A et al. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity. Toxicology 314(2-3), 209-220 (2013).
Goffart N, Kroonen J, Di Valentin E et al. Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling. Neuro Oncol. pii:nou144 (2014) (Epub ahead of print).
Garner JM, Fan M, Yang CH et al. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappaB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J. Biol. Chem. 288(36), 26167-26176 (2013).
Guo Q, Dong H, Liu X et al. A20 is overexpressed in glioma cells and may serve as a potential therapeutic target. Expert Opin. Ther. Targets 13(7), 733-741 (2009).
Honma K, Tsuzuki S, Nakagawa M et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 114(12), 2467-2475 (2009).
Hjelmeland AB, Wu Q, Wickman S et al. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol. 8(2), e1000319 (2010).
Kast RE, Karpel-Massler G, Halatsch ME. Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin Br. J. Pharmacol. 164(5), 1393-1396 (2011).
Wurth R, Pattarozzi A, Gatti M et al. Metformin selectively affects human glioblastoma tumor-initiating cell viability: a role for metformin-induced inhibition of Akt. Cell Cycle 12(1), 145-156 (2013).
Sato A, Sunayama J, Okada M et al. Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem. Cells Transl. Med. 1(11), 811-824 (2012).
Carmignani M, Volpe AR, Aldea M et al. Glioblastoma stem cells: a new target for metformin and arsenic trioxide. J. Biol. Regul. Homeost. Agents 28(1), 1-15 (2014).
ClinicalTrials.gov. Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM). http://clinicaltrials.gov
ClinicalTrials.gov. Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy (SMC 0712-13). http://clinicaltrials.gov
Piccirillo SG, Reynolds BA, Zanetti N et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444(7120), 761-765 (2006).
Gonzalez-Gomez P, Anselmo NP, Mira H. BMPs as therapeutic targets and biomarkers in astrocytic glioma. Biomed. Res. Int. 2014, 549742 (2014).
Li Q, Wijesekera O, Salas SJ et al. Mesenchymal stem cells from human fat engineered to secrete BMP4 are nononcogenic, suppress brain cancer, and prolong survival. Clin. Cancer Res. 20(9), 2375-2387 (2014).
Chirasani SR, Sternjak A, Wend P et al. Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain 133(Pt 7), 1961-1972 (2010).
Reguera-Nunez E, Roca C, Hardy E, De La Fuente M, Csaba N, Garcia-Fuentes M. Implantable controlled release devices for BMP-7 delivery and suppression of glioblastoma initiating cells. Biomaterials 35(9), 2859-2867 (2014).
Persano L, Pistollato F, Rampazzo E et al. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1alpha stability and MGMT expression. Cell Death Dis. 3, e412 (2012).
Yan K, Wu Q, Yan DH et al. Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. Genes Dev. 28(10), 1085-1100 (2014).
Varrault A, Gueydan C, Delalbre A et al. Zac1 regulates an imprinted gene network critically involved in the control of embryonic growth. Dev. Cell 11(5), 711-722 (2006).
Hide T, Takezaki T, Nakatani Y, Nakamura H, Kuratsu J, Kondo T. Sox11 prevents tumorigenesis of glioma-initiating cells by inducing neuronal differentiation. Cancer Res. 69(20), 7953-7959 (2009).
Zheng H, Ying H, Wiedemeyer R et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell 17(5), 497-509 (2010).
Aigner L, Bogdahn U. TGF-beta in neural stem cells and in tumors of the central nervous system. Cell Tissue Res. 331(1), 225-241 (2008).
Penuelas S, Anido J, Prieto-Sanchez RM et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15(4), 315-327 (2009).
Anido J, Saez-Borderias A, Gonzalez-Junca A et al. TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 18(6), 655-668 (2010).
Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 5(5), 504-514 (2009).
Ikushima H, Todo T, Ino Y et al. Gliomainitiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein. J. Biol. Chem. 286(48), 41434-41441 (2011).
Held-Feindt J, Schmelz S, Hattermann K, Mentlein R, Mehdorn HM, Sebens S. The neural adhesion molecule L1CAM confers chemoresistance in human glioblastomas. NeuroChem. Int. 61(7), 1183-1191 (2012).
Zhang N, Wei P, Gong A et al. FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 20(4), 427-442 (2011).
Zhang N, Wu X, Yang L et al. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clin. Cancer Res. 18(21), 5961-5971 (2012).
Joshi K, Banasavadi-Siddegowda Y, Mo X et al. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells 31(6), 1051-1063 (2013).
Minata M, Gu C, Joshi K et al. Multi-kinase inhibitor C1 triggers mitotic catastrophe of glioma stem cells mainly through MELK kinase inhibition. PLoS ONE 9(4), e92546 (2014).
De La Iglesia N, Puram SV, Bonni A. STAT3 regulation of glioblastoma pathogenesis. Curr. Mol. Med. 9(5), 580-590 (2009).
Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 27(10), 2383-2392 (2009).
Cao Y, Lathia JD, Eyler CE et al. Erythropoietin receptor signaling through STAT3 is required for glioma stem cell maintenance. Genes Cancer 1(1), 50-61 (2010).
Chiba S. Notch signaling in stem cell systems. Stem Cells 24(11), 2437-2447 (2006).
Fan X, Khaki L, Zhu TS et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheRes. and xenografts. Stem Cells 28(1), 5-16 (2010).
Guichet PO, Guelfi S, Teigell M et al. Notch1 stimulation induces a vascularization switch with pericyte-like cell differentiation of glioblastoma stem cells. Stem Cells doi:10.1002/stem.1767 (2014) (Epub ahead of print).
Suva ML, Riggi N, Janiszewska M et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 69(24), 9211-9218 (2009).
Kim E, Kim M, Woo DH et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23(6), 839-852 (2013).
Clement V, Sanchez P, De Tribolet N, Radovanovic I, Ruiz I Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 17(2), 165-172 (2007).
Takezaki T, Hide T, Takanaga H, Nakamura H, Kuratsu J, Kondo T. Essential role of the Hedgehog signaling pathway in human glioma-initiating cells. Cancer Sci. 102(7), 1306-1312 (2011).
Zbinden M, Duquet A, Lorente-Trigos A et al. NANOG regulates glioma stem cells and is essential in vivo acting in a crossfunctional network with GLI1 and p53. EMBO J. 29(15), 2659-2674 (2010).
Bar EE, Chaudhry A, Lin A et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25(10), 2524-2533 (2007).
Sarangi A, Valadez JG, Rush S, Abel TW, Thompson RC, Cooper MK. Targeted inhibition of the Hedgehog pathway in established malignant glioma xenografts enhances survival. Oncogene 28(39), 3468-3476 (2009).
Dixit D, Ghildiyal R, Anto NP, Ghosh S, Sharma V, Sen E. Guggulsterone sensitizes glioblastoma cells to Sonic hedgehog inhibitor SANT-1 induced apoptosis in a Ras/NFkappaB dependent manner. Cancer Lett. 336(2), 347-358 (2013).
Ding D, Lim KS, Eberhart CG. Arsenic trioxide inhibits Hedgehog, Notch and stem cell properties in glioblastoma neurospheres. Acta Neuropathol. Commun. 2(1), 31 (2014).
Wu J, Ji Z, Liu H et al. Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway. Toxicol. Lett. 220(1), 61-69 (2013).
Ulasov IV, Nandi S, Dey M, Sonabend AM, Lesniak MS. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol. Med. 17(1-2), 103-112 (2011).
Rasper M, Schafer A, Piontek G et al. Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. Neuro Oncol. 12(10), 1024-1033 (2010).
Soehngen E, Schaefer A, Koeritzer J et al. Hypoxia upregulates aldehyde dehydrogenase isoform 1 (ALDH1) expression and induces functional stem cell characteristics in human glioblastoma cells. Brain Tumor Pathol. 31(4), 247-256 (2014).
Schafer A, Teufel J, Ringel F et al. Aldehyde dehydrogenase 1A1-a new mediator of resistance to temozolomide in glioblastoma. Neuro. Oncol. 14(12), 1452-1464 (2012).
Liu P, Brown S, Goktug T et al. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br. J. Cancer 107(9), 1488-1497 (2012).
O'Driscoll M, Jeggo PA. The role of double-strand break repair-insights from human genetics. Nat. Rev. Genet. 7(1), 45-54 (2006).
Lavin MF. ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene 26(56), 7749-7758 (2007).
Lee JH, Paull TT. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 26(56), 7741-7748 (2007).
Iijima K, Ohara M, Seki R, Tauchi H. Dancing on damaged chromatin: functions of ATM and the RAD50/MRE11/NBS1 complex in cellular responses to DNA damage. J. Radiat. Res. 49(5), 451-464 (2008).
Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120), 756-760 (2006).
Cheng L, Wu Q, Huang Z et al. L1CAM regulates DNA damage checkpoInt. response of glioblastoma stem cells through NBS1. EMBO J. 30(5), 800-813 (2011).
Yuan M, Eberhart CG, Kai M. RNA binding protein RBM14 promotes radio-resistance in glioblastoma by regulating DNA repair and cell differentiation. Oncotarget 5(9), 2820-2826 (2014).
Wilson TE, Grawunder U, Lieber MR. Yeast DNA ligase IV mediates non-homologous DNA end joining. Nature 388(6641), 495-498 (1997).
Dronkert ML, Beverloo HB, Johnson RD, Hoeijmakers JH, Jasin M, Kanaar R. Mouse RAD54 affects DNA double-strand break repair and sister chromatid exchange. Mol. Cell Biol. 20(9), 3147-3156 (2000).
Lim YC, Roberts TL, Day BW et al. A role for homologous recombination and abnormal cell-cycle progression in radioresistance of glioma-initiating cells. Mol. Cancer Ther. 11(9), 1863-1872 (2012).
Ropolo M, Daga A, Griffero F et al. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol. Cancer Res. 7(3), 383-392 (2009).
Facchino S, Abdouh M, Chatoo W, Bernier G. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J. NeuroSci. 30(30), 10096-10111 (2010).
Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G. BMI1 sustains human glioblastoma multiforme stem cell renewal. J. NeuroSci. 29(28), 8884-8896 (2009).
Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl Acad. Sci. USA 104(2), 618-623 (2007).
Kim Y, Kim KH, Lee J et al. Wnt activation is implicated in glioblastoma radioresistance. Lab. Invest. 92(3), 466-473 (2012).
Wang J, Wakeman TP, Lathia JD et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 28(1), 17-28 (2010).
Osuka S, Sampetrean O, Shimizu T et al. IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells. Stem Cells 31(4), 627-640 (2013).
Murakami D, Okamoto I, Nagano O et al. Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. Oncogene 22(10), 1511-1516 (2003).
Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 95(12), 930-935 (2004).
Pietras A, Katz AM, Ekstrom EJ et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 14(3), 357-369 (2014).
Chang SH, Minai-Tehrani A, Shin JY et al. Beclin1-induced autophagy abrogates radioresistance of lung cancer cells by suppressing osteopontin. J. Radiat. Res. 53(3), 422-432 (2012).
Di Tomaso T, Mazzoleni S, Wang E et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 16(3), 800-813 (2010).
Wei J, Barr J, Kong LY et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin. Cancer Res. 16(2), 461-473 (2010).
Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro. Oncol. 8(3), 261-279 (2006).
Wu A, Wei J, Kong LY et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 12(11), 1113-1125 (2010).
Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190(7), 995-1004 (1999).
Williams L, Bradley L, Smith A, Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J. Immunol. 172(1), 567-576 (2004).
Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ. Shaping gene expression in activated and resting primary macrophages by IL-10. J. Immunol. 169(5), 2253-2263 (2002).
O'Farrell AM, Liu Y, Moore KW, Mui AL. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and-independent pathways. EMBO J. 17(4), 1006-1018 (1998).
Mancino A, Lawrence T. Nuclear factor-kappaB and tumor-associated macrophages. Clin. Cancer Res. 16(3), 784-789 (2010).
Wei J, Barr J, Kong LY et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol. Cancer Ther. 9(1), 67-78 (2010).
Hussain SF, Kong LY, Jordan J et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 67(20), 9630-9636 (2007).
Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51-72 (2013).
Fooksman DR, Vardhana S, Vasiliver-Shamis G et al. Functional anatomy of T cell activation and synapse formation. Annu. Rev. Immunol. 28, 79-105 (2010).
Ueda R, Iizuka Y, Yoshida K, Kawase T, Kawakami Y, Toda M. Identification of a human glioma antigen, SOX6, recognized by patients' sera. Oncogene 23(7), 1420-1427 (2004).
Ueda R, Ohkusu-Tsukada K, Fusaki N et al. Identification of HLA-A2-and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int. J. Cancer 126(4), 919-929 (2010).
Ahmed. N, Salsman VS, Kew Y et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res. 16(2), 474-485 (2010).
Pellegatta S, Finocchiaro G. Dendritic cell vaccines for cancer stem cells. Methods Mol. Biol. 568, 233-247 (2009).
Vik-Mo EO, Nyakas M, Mikkelsen BV et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol. ImmunoTher. 62(9), 1499-1509 (2013).
Lagasse E. Cancer stem cells with genetic instability: the best vehicle with the best engine for cancer. Gene Ther. 15(2), 136-142 (2008).